Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Cash from Investing Activities (2022 - 2025)

Taysha Gene Therapies' Cash from Investing Activities history spans 4 years, with the latest figure at -$48000.0 for Q3 2025.

  • For Q3 2025, Cash from Investing Activities fell 37.14% year-over-year to -$48000.0; the TTM value through Sep 2025 reached -$344000.0, up 10.88%, while the annual FY2024 figure was -$363000.0, 95.06% up from the prior year.
  • Cash from Investing Activities for Q3 2025 was -$48000.0 at Taysha Gene Therapies, down from $62000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $62000.0 in Q2 2025 and bottomed at -$11.4 million in Q1 2022.
  • The 4-year median for Cash from Investing Activities is -$201000.0 (2024), against an average of -$2.2 million.
  • The largest YoY upside for Cash from Investing Activities was 230.0% in 2024 against a maximum downside of 518.75% in 2024.
  • A 4-year view of Cash from Investing Activities shows it stood at -$2.4 million in 2022, then surged by 99.58% to -$10000.0 in 2023, then surged by 230.0% to $13000.0 in 2024, then plummeted by 469.23% to -$48000.0 in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Cash from Investing Activities are -$48000.0 (Q3 2025), $62000.0 (Q2 2025), and -$371000.0 (Q1 2025).